Author: Javier Fernandez-Diaz

11 Mar

Posted at 10:51h in News

Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients [Palma, March 4th 2025] – Laminar Pharma, a leader in the development of innovative cancer therapy based on membrane lipid therapy,...

17 Jun

Posted at 11:38h in News, Press, Uncategorized

140 patients have been recruited at sites in Spain, Italy, France and United Kingdom. The open readout of the trial is expected by late 2024. Laminar aims to submit regulatory filings or conditional marketing authorization by early 2025. Laminar Pharmaceuticals S.A., a clinical-stage biotechnological company developing novel therapies...

06 Mar

Posted at 08:10h in News, Press, Uncategorized

The independent data monitoring committee (IDMC) has recommended continuation of CLINGLIO without modification after its assessment of LAM561 interim efficacy in newly diagnosed Glioblastoma. This follows the previous recommendation in relation to safety. CLINGLIO remains on track to have its open readout at 66 progression...

23 Mar

Posted at 17:13h in Blog, News

“If someone has done it before, I can do it too – if no one has done it, I can be the first”: for 30 years, this compass has guided the prolific scientific career of Dr. Pablo Escribá, founder and CEO of Laminar Pharma....